L-Deprenyl (Selegeline) is an enzyme-activated irreversible inhibitor
of monoamine oxidase B (MAO B; EC 1.4.3.4). It is used to treat Parkin
son's disease at a dose of 5 mg twice a day. Since enzyme inhibition i
s irreversible, the recovery of functional enzyme activity after withd
rawal from L-deprenyl requires the synthesis of new enzyme. We have me
asured a 40 day half-time for brain MAO B synthesis in Parkinson's dis
ease and in normal subjects after withdrawal from L-deprenyl. This is
the first measurement of the synthesis rate of a specific protein in t
he living human brain. L-Deprenyl is currently used by 50,000 patients
with Parkinson's disease in the United States and its use is expected
to increase with reports that it may be beneficial in Alzheimer's dis
ease. The slow turnover of brain MAO B suggests that the current clini
cal dose of L-deprenyl may be excessive and that the clinical efficacy
of reduced dosing should be evaluated. Such an evaluation may have me
chanistic importance as well as an impact on reducing the side effects
and the costs arising from excessive drug use. (C) 1994 Wiley-Liss, I
nc.